Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Oct 30, 2023 8:35am
164 Views
Post# 35706906

RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumors

RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumorsYes and the thing I never realized at first either is CAR-T therapy is quite toxic and does destroy a lot of normal cells too, that's ok in WBC because your body is constantly making more white cells and will be replaced fairly quickly.

If you direct a CAR-T to say colon cancer, you could destroy your colon and it could be irreparable.

So you need a much more specific solution or targeting. 

Pelareorep with a CAR-T attached is a perfect solution because it only infects cancer cells and will deliver the CAR-T to the cancer cell only.  Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!


<< Previous
Bullboard Posts
Next >>